TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21060031

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg daily for 7 days followed by 75 mg daily for 21 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Gabapentin (300 mg once per day for 3 days, then 300 mg twice per day for 3 days, then 300 mg three times per day for 22 days)
Number of subjects: 66
Study: 18058343

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (10 weeks)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 722
Study: 15859023

Group type: EXPERIMENTAL
Intervention: 7.5% NaCl infusion
Number of subjects: 14
Study: 12223249

Group type: EXPERIMENTAL
Intervention: 15-month family intervention
Number of subjects: 0
Study: 9788455

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU for mothers, 25000 IU for infants)
Number of subjects: 9424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9424
Study: 7626570

Group type: EXPERIMENTAL
Intervention: One drop regimen of dapiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 + 1 drop regimen of dapiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 + 2 drop regimen of dapiprazole (reference)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2791122

Group type: EXPERIMENTAL
Intervention: Gamma-neutron irradiation using 252Cf, physical dose 2 Gy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional sources of radiation gamma 226Ra
Number of subjects: 20
Study: 31225839

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention consisting of four one‐on‐one sessions with a nurse interventionist during the patient's first, second, fourth, and sixth week of radiation treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 18
Study: 28974568

Group type: EXPERIMENTAL
Intervention: SBP-VVV 4th quartile (≥17.34 mm Hg)
Number of subjects: 3843

Group type: EXPERIMENTAL
Intervention: SBP-VVV 3rd quartile (13.86-17.33 mm Hg)
Number of subjects: 3843

Group type: EXPERIMENTAL
Intervention: SBP-SD as a continuous variable
Number of subjects: 3843

Group type: EXPERIMENTAL
Intervention: SBP-VVV quartiles (1st to 4th)
Number of subjects: 3843
Study: 26269446

Group type: EXPERIMENTAL
Intervention: Powered knee-ankle-foot orthosis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Drop-locked knee-ankle-foot orthosis
Number of subjects: 7
Study: 23880908

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (n=22)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 46
Study: 22910758

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 153962

Group type: COMPARATOR
Intervention: Intensive dose statin therapy
Number of subjects: 153962

Group type: COMPARATOR
Intervention: Fibrate therapy
Number of subjects: 153962
Study: 19261367

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (verapamil and diltiazem)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (verapamil)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (diltiazem)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 206
Study: 17191143

Group type: EXPERIMENTAL
Intervention: Repeated mailing condition (received the summary booklet plus 7 additional booklets)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Single mailing condition (received one booklet summarizing all of the relapse prevention information)
Number of subjects: 169
Study: 15183850

Group type: EXPERIMENTAL
Intervention: 10% solution (v/v) of essential oil of Australian lemon myrtle (Backhousia citriodora)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle (olive oil)
Number of subjects: 31
Study: 11773176

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PCT) consisting of two cycles of mitomycin (6 mg/m(2), day 1), ifosfamide (1.5 g/m(2), days 1 to 3), and cisplatin (30 mg/m(2), days 1 to 3), plus two additional postoperative cycles for responding patients.
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PCT)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Primary surgery (PRS)
Number of subjects: 355
Study: 9538626

Group type: EXPERIMENTAL
Intervention: Levosulpiride 25mg t.i.d. for 3 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Levosulpiride
Number of subjects: 42
Study: 8076723

Group type: EXPERIMENTAL
Intervention: Clinician-initiated telephone intervention at 6, 9, and 12 weeks postfitting.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group encouraged to contact the center only at the time of dispensing.
Number of subjects: 60
Study: 2511687

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (mean dose 12.9 mg; range 7.7‐14.9)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerine (5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (nitro TTS 10)
Number of subjects: 36
Study: 1066200

Group type: EXPERIMENTAL
Intervention: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied every 6 months
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied once each year
Number of subjects: 464

Group type: COMPARATOR
Intervention: Non-fluoride zirconium silicate paste (tzircate Prophylaxis Paste) applied once each year
Number of subjects: 464
Study: 31248461

Group type: EXPERIMENTAL
Intervention: 12MP + Tet + TLR agonist without IFA (V0)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 12MP + Tet + TLR agonist with IFA (V1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 12MP + Tet + TLR agonist with IFA (V6)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LPS (cohort 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: polyICLC (cohort 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Treatment-related dose-limiting toxicities (DLTs)
Number of subjects: 51
Study: 28403406

Group type: EXPERIMENTAL
Intervention: C-E clamp technique
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: V-E clamp technique
Number of subjects: 81
Study: 24977698

Group type: EXPERIMENTAL
Intervention: P30 (30 s rest)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: P60 (60 s rest)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: P120 (120 s rest)
Number of subjects: 19
Study: 23823377

Group type: EXPERIMENTAL
Intervention: CO‐ED system (computer‐assisted instruction about major hypertension topics)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Internet search (search engine for information about hypertension)
Number of subjects: 60
Study: 21730307

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d for 3 days before surgery
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 42
Study: 18538111

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 32
Study: 15946638

Group type: EXPERIMENTAL
Intervention: Handsfree phone mode
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Handheld phone mode
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dialling (both phone modes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conversation (both phone modes)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dialling and conversation (both phone modes)
Number of subjects: 48
Study: 12117049

Group type: EXPERIMENTAL
Intervention: TJ-96 (2.5 g orally 3 times daily for 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TJ-96
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10428573

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise mode
Number of subjects: 10
Study: 7539633

Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine, RNA, and omega-3 fatty acids
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous placebo diet
Number of subjects: 42
Study: 2280848

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 507792

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 46
Study: 28739019

Group type: EXPERIMENTAL
Intervention: Stabilization exercises plus electrotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine exercises plus electrotherapy
Number of subjects: 41
Study: 27289482

Group type: EXPERIMENTAL
Intervention: Local fasciocutaneous perforator flap (lFPF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free Gracilis flap (fGF)
Number of subjects: 30
Study: 25446057

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 23522721

Group type: COMPARATOR
Intervention: NSAID therapy (n=24)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (n=11)
Number of subjects: 35
Study: 20648213

Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 70

Group type: COMPARATOR
Intervention: Local anesthetic mixed with non-particulate betamethasone
Number of subjects: 70
Study: 18413332

Group type: EXPERIMENTAL
Intervention: 80 mg extended-release fluvastatin every day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 40 mg immediate-release fluvastatin twice a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15641902

Group type: EXPERIMENTAL
Intervention: Auditory modality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vision and touch
Number of subjects: 0
Study: 12639651

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 10832825

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg oral once daily for up to 6 months
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study: 9093182

Group type: EXPERIMENTAL
Intervention: Early follicular endometrial priming with 2 mg 17 beta‐E2 twice per day (group A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Midfollicular endometrial priming with 1 to 2 mg/d of 17 beta‐E2 (group B)
Number of subjects: 14
Study: 8457235

Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Piracetam 9.6 g
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Piracetam (4.8 g and 9.6 g)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 5
Study: 3954834

Group type: EXPERIMENTAL
Intervention: 0.58 g alcohol/kg body wt as whisky or lager
Number of subjects: 9

Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 9
Study: 31175689

Group type: EXPERIMENTAL
Intervention: High protein dose (exact dosage not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low protein dose (exact dosage not specified)
Number of subjects: 0
Study: 29790221

Group type: EXPERIMENTAL
Intervention: 5-year lifestyle intervention (cholesterol-lowering dietary changes, weight loss, and stopping smoking)
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: 5-year lifestyle intervention
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1216
Study: 27246689

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) plus cytotoxic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) 15 mg/kg dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) 10 mg/kg dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) with paclitaxel once per week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) plus paclitaxel once per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 24525158

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 173
Study: 23158530

Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-eluting balloon (DEB)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 182
Study: 20579957

Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical length <25 mm
Number of subjects: 0
Study: 18085343

Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with extended lymphadenectomy
Number of subjects: 424

Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy with standard lymphadenectomy
Number of subjects: 424
Study: 15814873

Group type: EXPERIMENTAL
Intervention: Enriched drink
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 12215585

Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation (AF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coronary artery disease (CAD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study: 10379631

Group type: EXPERIMENTAL
Intervention: Priming dose of tubocurarine (TC) 0.15 mg x kg(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming dose of vecuronium (VEC) 0.015 mg x kg(‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intubation dose of tubocurarine (TC) 0.6 mg x kg(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming with tubocurarine (TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Priming with vecuronium (VEC)
Number of subjects: 0
Study: 8704079

Group type: EXPERIMENTAL
Intervention: Metamizol (1 g/100 ml NaCl 0.9% intravenous over 15 min) plus diclofenac (100 mg suppository)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study: 1473857

Group type: EXPERIMENTAL
Intervention: 1.5 g paracetamol coingested with a meal of white bread
Number of subjects: 15

Group type: COMPARATOR
Intervention: White bread meal without paracetamol
Number of subjects: 15
Study: 6330872

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31633318

Group type: EXPERIMENTAL
Intervention: Ultrasonic preparation (Crown Prep, Mectron, Carasco, Italy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional technique (high-speed contra-angle handpiece, Kavo, Biberach, Germany)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ultrasonic preparation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 32
Study: 29410543

Group type: EXPERIMENTAL
Intervention: Modified Tochen's formula (birth weight + 5 cm)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tochen's formula
Number of subjects: 67
Study: 27712311

Group type: EXPERIMENTAL
Intervention: Specific picture book and information sheet
Number of subjects: 104

Group type: COMPARATOR
Intervention: Routine information and specific picture book
Number of subjects: 104
Study: 23909911

Group type: EXPERIMENTAL
Intervention: Development of nephropathy (incidence of urinary albumin excretion rate > 40 mg/24 h)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Progression of retinopathy (3-step change in Early Treatment Diabetic Retinopathy Study score)
Number of subjects: 1365
Study: 22011531

Group type: EXPERIMENTAL
Intervention: Infection control strategies to reduce MRSA transmission
Number of subjects: 5512

Group type: EXPERIMENTAL
Intervention: CA-MRSA genotype (USA300, USA400, USA1000)
Number of subjects: 5512

Group type: EXPERIMENTAL
Intervention: Molecular typing of MRSA isolates
Number of subjects: 5512
Study: 19049340

Group type: EXPERIMENTAL
Intervention: ACE-011 (0.01 to 3.0 mg/kg intravenously or 0.03 to 0.1 mg/kg subcutaneously)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ACE-011
Number of subjects: 48
Study: 17116057

Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension (LC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Vaginal suburethral slingplasty (SPARC)
Number of subjects: 97
Study: 14993114

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 121
Study: 11732275

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU daily) and selegiline (10 mg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Symptomatic treatment (Control)
Number of subjects: 67
Study: 9164205

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 50 mg/m2 for nine courses
Number of subjects: 607

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 plus cyclophosphamide 750 mg/m2 every 21 days for six courses
Number of subjects: 607
Study: 8425936

Group type: EXPERIMENTAL
Intervention: SKT test battery
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: SKT memory and attention factor scores
Number of subjects: 265
Study: 2438553

Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29316186

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Renal denervation
Number of subjects: 24
Study: 27062950

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (10-week duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 23796239

Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (without KMC)
Number of subjects: 50
Study: 23525525

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20950457

Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib2.5 [Kft]
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib
Number of subjects: 299

Group type: COMPARATOR
Intervention: DTPw-HBV/Hib2.5
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib2.5 [Kft] and DTPw-HBV/Hib
Number of subjects: 299
Study: 18259973

Group type: EXPERIMENTAL
Intervention: Tiotropium (n = 78)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo (n = 82)
Number of subjects: 166
Study: 20522483

Group type: EXPERIMENTAL
Intervention: Bathers
Number of subjects: 1303
Study: 16293781

Group type: EXPERIMENTAL
Intervention: Intensive multitherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study: 12164596

Group type: EXPERIMENTAL
Intervention: 25 per cent wt/vol. glucose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 per cent wt/vol. glucose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 60
Study: 9725478

Group type: EXPERIMENTAL
Intervention: Megaloporous sustained-release tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrophil matrix tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Floating slow-release tablets with food
Number of subjects: 24

Group type: COMPARATOR
Intervention: Floating slow-release tablets without food
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rapid release oxprenolol tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fasting tablets (sustained-release)
Number of subjects: 24
Study: 7913498

Group type: EXPERIMENTAL
Intervention: E2078 (5.0 to 10.0 mg, i.m.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E2078 (single dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E2078 (repeated dose, 5.0 mg t.i.d. for 4 and 1/3 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E2078 (repeated doses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E2078 (single administration)
Number of subjects: 21
Study: 3189201

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1938

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1938
Study: 11891095

Group type: EXPERIMENTAL
Intervention: Carbamazepine (15 mg/kg per day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodium valproate (20-25 mg/kg per day)
Number of subjects: 24
Study: 30101910

Group type: EXPERIMENTAL
Intervention: Adjusted R-CHOP doses according to a unified dose-attenuation system (UNI group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Adjusted R-CHOP doses according to physicians' decisions (PHY group)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Patients aged >70 years in the UNI group
Number of subjects: 115

Group type: COMPARATOR
Intervention: Patients aged >70 years in the PHY group
Number of subjects: 115
Study: 27020664

Group type: EXPERIMENTAL
Intervention: Stent thrombosis (ST) in patients with AMI after PCI
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Patients with ST
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Independent predictors of ST
Number of subjects: 136
Study: 24842494

Group type: EXPERIMENTAL
Intervention: Bone graft sealing
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cement sealing
Number of subjects: 201

Group type: COMPARATOR
Intervention: Unsealed canal
Number of subjects: 201
Study: 22366446

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) - 12 twice-weekly 60 min sessions
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 59
Study: 20177349

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (180 microg menakinon‐7)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 18691211

Group type: EXPERIMENTAL
Intervention: Paramedics with extended skills (PPs) treating patients in the community.
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Standard practice of EMS transfer and ED treatment (Control).
Number of subjects: 2025